KAPA

$0.00

(

+0.00%

)
Quote details

stock

Kairos Pharma, Ltd.

NYSE MKT | KAPA

0.83

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$15.35M

Market Cap

-

P/E Ratio

-0.31

EPS

$2.13

52 Week High

$0.40

52 Week Low

HEALTHCARE

Sector

KAPA Chart

Recent Chart
Price Action

KAPA Technicals

Tags:

KAPA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$160K
Total Revenue $0
Cost Of Revenue $160K
Costof Goods And Services Sold $160K
Operating Income -$2.3M
Selling General And Administrative $1.9M
Research And Development $414K
Operating Expenses $2.2M
Investment Income Net -
Net Interest Income -$859K
Interest Income -
Interest Expense $859K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $160K
Income Before Tax -$2.6M
Income Tax Expense -$2.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$2.6M
Comprehensive Income Net Of Tax -
Ebit -$1.7M
Ebitda -$1.6M
Net Income -$2.6M

Revenue & Profitability

Earnings Performance

KAPA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $6.2M
Total Current Assets $4.2M
Cash And Cash Equivalents At Carrying Value $1.3M
Cash And Short Term Investments $1.3M
Inventory -
Current Net Receivables -
Total Non Current Assets $2M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $222K
Intangible Assets Excluding Goodwill $222K
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.9M
Other Non Current Assets -
Total Liabilities $1.4M
Total Current Liabilities $992K
Current Accounts Payable $992K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $448K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $992K
Other Non Current Liabilities -
Total Shareholder Equity $4.8M
Treasury Stock -
Retained Earnings -$8.8M
Common Stock $14K
Common Stock Shares Outstanding $11M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$4M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $160K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $5.1M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$2.6M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$160K
Total Revenue $0
Cost Of Revenue $160K
Costof Goods And Services Sold $160K
Operating Income -$2.3M
Selling General And Administrative $1.9M
Research And Development $414K
Operating Expenses $2.2M
Investment Income Net -
Net Interest Income -$859K
Interest Income -
Interest Expense $859K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $160K
Income Before Tax -$2.6M
Income Tax Expense -$2.6M
Interest And Debt Expense -
Net Income From Continuing Operations -$2.6M
Comprehensive Income Net Of Tax -
Ebit -$1.7M
Ebitda -$1.6M
Net Income -$2.6M

KAPA Profile

Kairos Pharma, Ltd. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Kairos Pharma, Ltd. (KAPA) is a dynamic clinical-stage biopharmaceutical company based in Los Angeles, California, dedicated to pioneering innovative therapies for cancer. The firm is advancing a robust pipeline of proprietary drug candidates designed to address critical unmet needs in oncology, signifying its commitment to improving treatment outcomes. With a strong focus on research and development, Kairos Pharma is strategically positioned to capitalize on the evolving biopharmaceutical landscape, making it a compelling investment opportunity for institutional investors seeking exposure to transformative advancements in cancer care.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+54.72%
$1.64
VINE
+10.76%
$0.39
AMZE
+28.66%
$0.50
IPG
-1.95%
$24.57
TLRY
-20.11%
$0.82
BITF
+12.58%
$3.49
NVDA
-1.76%
$177.08
AXDX
-61.36%
$0.03
YGMZ
-10.65%
$0.10
INTC
+2.73%
$36.81
ADAP
-15.14%
$0.05
HOOD
+10.92%
$128.20
RUBI
-25.80%
$0.16
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ASST
+2.65%
$1.16
RIG
+6.17%
$4.30
SRM
+53.27%
$10.30
BIYA
+11.30%
$0.28
AGNC
+1.53%
$10.56
BAC
+0.97%
$52.99
INHD
+2.21%
$0.23
CLSK
+14.57%
$15.41
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BMNR
+6.26%
$33.72
MTSR
-0.35%
$70.50
SNAP
+0.14%
$7.62
ONMD
+45.07%
$2.06
TSLA
+0.55%
$428.96
PCG
+1.78%
$16.01
CIFR
+10.05%
$21.07
PLUG
+2.09%
$2.02
ADTX
+19.42%
$3.75
AFMD
-34.94%
$0.18
MARA
+5.02%
$11.66
GPUS
-6.69%
$0.31
NVTS
+3.86%
$8.34
DEFT
+11.51%
$1.55
WULF
+7.27%
$15.92
NIO
+0.36%
$5.48
KWM
+12.77%
$0.74
CHR
-4.18%
$0.04
BMNU
+14.89%
$8.64
F
+0.68%
$13.28
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
AMCR
+1.29%
$8.62
ONDS
-2.81%
$8.00
TEVA
+5.32%
$26.32
GOOGL
-0.60%
$318.02
SOFI
+3.18%
$29.39
VALE
+0.31%
$12.54
BTG
+3.37%
$4.62
CRCL
+11.05%
$80.67
KDLY
+7.20%
$0.49
AAL
+0.60%
$14.01
DVLT
-6.33%
$1.99
SMX
+222.58%
$56.13
CSCO
-0.32%
$76.07
IBRX
+11.50%
$2.37
CAN
+12.59%
$1.03
IREN
-0.44%
$48.23
BTBT
+2.58%
$2.38
BURU
+5.44%
$0.23
SAND
-6.04%
$12.12
RIOT
+9.45%
$16.37
NGD
+5.86%
$8.30
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
HBI
-0.75%
$6.54
APLD
+7.21%
$26.74
PFE
+0.19%
$25.75
GRAB
+2.67%
$5.46
AG
+12.27%
$15.16
GOOG
-0.73%
$317.92
AMD
+0.97%
$216.32
CRCG
+21.27%
$2.85
KO
+0.37%
$72.88
TMC
+14.32%
$6.66
C
+1.31%
$102.50
CRCA
+22.96%
$4.52
SNDK
+4.28%
$224.25
ABVE
+16.17%
$3.05
NEHC
+8.33%
$5.07
RIVN
+4.57%
$16.92
PLTR
+0.75%
$167.01
COMP
-0.76%
$10.42
CDE
+6.02%
$17.16
ACHR
+4.07%
$7.79
RF
+0.11%
$25.45
KEY
+0.16%
$18.40
MSTR
+2.73%
$180.44
DNN
+1.09%
$2.58
IVP
-9.12%
$0.12
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+54.72%
$1.64
VINE
+10.76%
$0.39
AMZE
+28.66%
$0.50
IPG
-1.95%
$24.57
TLRY
-20.11%
$0.82
BITF
+12.58%
$3.49
NVDA
-1.76%
$177.08
AXDX
-61.36%
$0.03
YGMZ
-10.65%
$0.10
INTC
+2.73%
$36.81
ADAP
-15.14%
$0.05
HOOD
+10.92%
$128.20
RUBI
-25.80%
$0.16
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
ASST
+2.65%
$1.16
RIG
+6.17%
$4.30
SRM
+53.27%
$10.30
BIYA
+11.30%
$0.28
AGNC
+1.53%
$10.56
BAC
+0.97%
$52.99
INHD
+2.21%
$0.23
CLSK
+14.57%
$15.41
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BMNR
+6.26%
$33.72
MTSR
-0.35%
$70.50
SNAP
+0.14%
$7.62
ONMD
+45.07%
$2.06
TSLA
+0.55%
$428.96
PCG
+1.78%
$16.01
CIFR
+10.05%
$21.07
PLUG
+2.09%
$2.02
ADTX
+19.42%
$3.75
AFMD
-34.94%
$0.18
MARA
+5.02%
$11.66
GPUS
-6.69%
$0.31
NVTS
+3.86%
$8.34
DEFT
+11.51%
$1.55
WULF
+7.27%
$15.92
NIO
+0.36%
$5.48
KWM
+12.77%
$0.74
CHR
-4.18%
$0.04
BMNU
+14.89%
$8.64
F
+0.68%
$13.28
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
AMCR
+1.29%
$8.62
ONDS
-2.81%
$8.00
TEVA
+5.32%
$26.32
GOOGL
-0.60%
$318.02
SOFI
+3.18%
$29.39
VALE
+0.31%
$12.54
BTG
+3.37%
$4.62
CRCL
+11.05%
$80.67
KDLY
+7.20%
$0.49
AAL
+0.60%
$14.01
DVLT
-6.33%
$1.99
SMX
+222.58%
$56.13
CSCO
-0.32%
$76.07
IBRX
+11.50%
$2.37
CAN
+12.59%
$1.03
IREN
-0.44%
$48.23
BTBT
+2.58%
$2.38
BURU
+5.44%
$0.23
SAND
-6.04%
$12.12
RIOT
+9.45%
$16.37
NGD
+5.86%
$8.30
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
HBI
-0.75%
$6.54
APLD
+7.21%
$26.74
PFE
+0.19%
$25.75
GRAB
+2.67%
$5.46
AG
+12.27%
$15.16
GOOG
-0.73%
$317.92
AMD
+0.97%
$216.32
CRCG
+21.27%
$2.85
KO
+0.37%
$72.88
TMC
+14.32%
$6.66
C
+1.31%
$102.50
CRCA
+22.96%
$4.52
SNDK
+4.28%
$224.25
ABVE
+16.17%
$3.05
NEHC
+8.33%
$5.07
RIVN
+4.57%
$16.92
PLTR
+0.75%
$167.01
COMP
-0.76%
$10.42
CDE
+6.02%
$17.16
ACHR
+4.07%
$7.79
RF
+0.11%
$25.45
KEY
+0.16%
$18.40
MSTR
+2.73%
$180.44
DNN
+1.09%
$2.58
IVP
-9.12%
$0.12

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.